Neonatal and Infant Erythrodermas: Contribution of Early Skin Biopsy in Severe Cases

Pelage is recruiting for phase 2 trials, showing promise for treating bald regions. The discussion highlights its potential effectiveness based on its mechanism of action.

Pelage Pharmaceuticals' PP405 aims to treat hair loss by reactivating dormant hair follicle stem cells, showing promising results in early trials. The company plans to present their findings at the American Academy of Dermatology Annual Meeting in 2026.

Tretinoin can irritate seborrheic dermatitis, but using it with a moisturizer on calm skin may help. Parallel Health's skin microbiome testing and phage therapy are suggested for persistent issues.

A user noticed irregularities on their scalp using a digital microscope and suspects scarring alopecia, despite using minoxidil and finasteride. Other users suggest seborrheic dermatitis as a possible cause and recommend treatments like ketoconazole shampoo, sulfur soap, selenium sulfide shampoo, and apple cider vinegar rinses.

PP405 is advancing to Phase 2b trials, showing promise from Phase 2a. It may be available in 3-6 years, with trials using a topical gel.

A new treatment using dermal sheath cup cells may regrow hair and could require repeat treatments every 8 years. Users discuss ongoing trials and plan to use finasteride and minoxidil until the treatment is available.